In order to improve the cost-effectiveness and interest of patients and their families, we recommend MMR protein IHC (MLH1, PMS2, MSH2, and MSH6) to be included in the diagnostic guidelines for the general screening of LS-associated UTUC (27, 28). This evidence concerns the gene PMS2 and renal pelvis/ureter urothelial carcinoma.